Cancer genetics: mouse models of intestinal cancer

A R Clarke1

  • 1School of Biosciences, Cardiff University, Cardiff CF10 3US, U.K. ClarkeAR@cardiff.ac.uk

Insights

Researchers used inducible gene deletion in mice to study intestinal cancer. Loss of the Apc gene caused differentiation failure, aberrant proliferation, and apoptosis, revealing early carcinogenesis events and potential therapeutic targets like Sparc.

Area of Science:

  • Molecular biology
  • Cancer research
  • Genetics

Background:

  • Advances in mouse cancer modeling enable temporal and spatial control of gene expression.
  • Loss of the tumor-suppressor gene Apc (adenomatous polyposis coli) is linked to human and murine intestinal neoplasia.
  • The precise mechanisms by which Apc influences tumorigenesis are not fully understood.

Purpose of the Study:

  • To review the use of inducible gene deletion strategies in adult murine epithelium to study tumorigenesis.
  • To characterize the direct consequences of Apc gene inactivation in the murine intestine.
  • To identify potential therapeutic targets and understand gene interactions in Apc-driven carcinogenesis.

Main Methods:

  • Utilizing inducible strategies for co-ordinate gene deletion in adult murine epithelium.
  • Employing transcriptome analysis to identify potential therapeutic targets.
  • Investigating the effects of co-deleting other genes (cyclin D1, Tcf-1, p53, c-Myc, Mbd2) with Apc.

Main Results:

  • Apc inactivation led to failed differentiation, impaired migration, aberrant proliferation, and apoptosis induction.
  • Sparc (secreted protein acidic and rich in cysteine) deficiency was shown to suppress adenoma formation.
  • Loss of cyclin D1, Tcf-1, and p53 had minimal impact, while loss of c-Myc or Mbd2 significantly altered outcomes following Apc loss.

Conclusions:

  • Inducible gene deletion models provide a powerful tool to define early events in intestinal carcinogenesis.
  • Apc plays a critical role in intestinal epithelial homeostasis, and its inactivation triggers multiple cellular defects.
  • Sparc emerges as a potential therapeutic target, and the study highlights the complex interplay of genes in modulating Apc-driven tumorigenesis.